Mobocertinib succinate

Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR . Mobocertinib succinate can be used in NSCLC research In Vitro Mobocertinib succinate (1.5 nM-10 μM; 7 days) inhibits LU0387 (NPH) cells with IC 50 of 21 nM. Mobocertinib succinate (2 h) potently inhibits EGFR with common activating mutations (HCC827 (D), HCC4011 (L)) or with a T790M mutation (H1975 (LT)) more potently than WT EGFR (A431 (WT)). Mobocertinib succinate (0.1 nM-1 μM; 6 h) inhibits pEGFR and pERK1/2 in CUTO14 (ASV) cells. Mobocertinib succinate (0.3 nM-1 μM; 6 h) inhibits EGFR and downstream signaling. Mobocertinib succinate (0.01, 0.1 and 1 μM; 6 h) inhibits HER2 signaling in H1781 (HER2 Exon 20 G776>VC ), Ba/F3 (HER2 exon 20 YVMA ) cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: LU0387 (NPH) cells Concentration: 1.5 nM-10 μM Incubation Time: 7 days Result: Showed good inhibition activity for LU0387 (NPH) cells with IC 50 of 21 nM. Cell Viability AssayCell Line: A431 (WT), HCC827 (D), HCC4011 (L), H1975 (LT) cells Concentration: Incubation Time: 2 h Result: Inhibited EGFR with common activating mutations of HCC827 (D), HCC4011 (L) cells and T790M mutation of H1975 (LT) with IC 50 s of 4, 1.3 and 9.8 nM respectively, which more potently than WT EGFR (A431 (WT); IC 50 of 35 nM). Western Blot AnalysisCell Line: CUTO14 (ASV) cells Concentration: 0.1 nM-1 μM Incubation Time: 6 h Result: Robustly inhibited EGFR signaling, reaching 80% and 100% inhibition of phosphorylated EGFR (pEGFR) at concentrations of 100 nM and 1 μM, respectively. Western Blot AnalysisCell Line: HCC827 (D), HCC4011 (L), H1975 (LT) cells Concentration: 0.3 nM-1 μM Incubation Time: 6 h Result: Potently inhibited EGFR and downstream signaling in HCC827 (D), HCC4011 (L) and H1975 (LT) cells. Western Blot AnalysisCell Line: H1781 (HER2 Exon 20 G776>VC ), Ba/F3 (HER2 exon 20 YVMA ) cells Concentration: 0.01, 0.1 and 1 μM Incubation Time: 6 h Result: Inhibited HER2 signaling in H1781 and Ba/F3-HER2 exon 20 YVMA mutant cells at 0.1 μM with significantly decreased phosphorylations of HER2, AKT, and ERK1/2 in a dose-dependent manner. In Vivo Mobocertinib succinate (3, 10, 30 mg/kg; p.o.; once daily for 20 days) significantly induces tumor growth inhibition . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Athymic Nude-Foxn1 nu mice (human NSCLC H1975 LT tumor model) . Dosage: 3, 10, 30 mg/kg Administration: Oral; once daily for 20 days. Result: Decreased the mean tumor volume by 44% and 92% when at 3 mg/kg and 10 mg/kg, respectively, relative to the tumor size of vehicle group. Induced a 76% tumor regression relative to the pretreatment tumor size at 30 mg/kg. Form:Solid IC50& Target:EGFR exon 20 insertion HER2 EGFR (WT)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet